# LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

> **NCT07737925** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Thomas Jefferson University** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Castrate Resistant Prostate Cancer

## Interventions

- **DRUG:** Xaluritamig

## Key facts

- **NCT ID:** NCT07737925
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2030-10
- **Final completion:** 2031-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07737925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07737925, "LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07737925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*